| Evaluation of a cosmetic gel containing retinol palmitate for its improvement effect on wrinkles | Evaluation of a cosmetic gel containing retinol palmitate for its improvement effect on wrinkles | JPRN-jRCTs031200260 |
| The effect of dexamethasone palmitate on the postoperative pain intensity in patients receiving pain control after arthroscopic shoulder surgery using brachial plexus block: a randomized controlled trial | The effect of dexamethasone palmitate on the postoperative pain intensity in patients receiving pain control after arthroscopic shoulder surgery using brachial plexus block: a randomized controlled trial | KCT0010028 |
| Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment | Differences in Lipid and Cognitive Change Between One-month and 3-month Paliperidone Palmitate Treatment in Stable Schizophrenia | NCT04754750 |
| Epidural injection of Dexamethasone palmitate vs. betamethasone for lumbar disk herniation, a multi-center non-inferiority randomized double blind controlled trial | Epidural injection of Dexamethasone palmitate vs. betamethasone for lumbar disk herniation, a non-inferiority randomized double blind controlled trial | ChiCTR2400093970 |
| A multiple-dose BE study with clinical endpoint comparing Paliperidone Palmitate Prolonged Release suspension for injection 100 mg of Qilu Pharmaceuticals Co., Ltd with Xeplion Prolonged Release suspension for Injection 100 mg of Janssen-Cilag International NV in subjects with schizophrenia. | An open label, multi-center, balanced, randomized, two-treatment, single-period, parallel group, multiple dose, steady state, bioequivalence study of Paliperidone Palmitate Prolonged Release Suspension for injection 100 mg of Qilu Pharmaceuticals Co., Ltd with Xeplion Prolonged Release suspension for Injection 100 mg of Janssen-Cilag International NV in subjects with schizophrenia. - NIL | CTRI/2024/11/077360 |
| A Prospective, Randomized, Controlled, Multicenter Clinical Study of Dexamethasone Palmitate in the Treatment of Sterile Inflammatory Pain | A Prospective, Randomized, Controlled, Multicenter Clinical Study of Dexamethasone Palmitate in the Treatment of Sterile Inflammatory Pain | ChiCTR2500101190 |
| A multicentre, real-world study on the analysis of factors related to sustained treatment with domestically produced paliperidone palmitate injection | A multicentre, real-world study on the analysis of factors related to sustained treatment with domestically produced paliperidone palmitate injection | ChiCTR2400092854 |
| A single-dose BE study comparing Paliperidone Palmitate Prolonged Release suspension for injection 100 mg with Xeplion Prolonged Release suspension for Injection 100 mg in subjects with schizophrenia. | A multicenter, open-label, balanced, randomized, two-treatment, single-period, parallel-group, single-dose, bioequivalence study of Paliperidone palmitate 100 mg prolonged-release suspension for injection of Qilu Pharmaceuticals Co., Ltd. with Xeplion (paliperidone) 100 mg prolonged-release suspension for injection of Janssen-Cilag International NV in subjects with schizophrenia. - NIL | CTRI/2024/11/077367 |
| Pharmacokinetic study of two formulations of paliperidone palmitate extended-release injectable suspension in patients with schizophrenia. | An Open Label, Randomized, Multicenter, Multiple-dose, Two-treatment, Single-period, Parallel,Steady State Bioequivalence Study of Paliperidone Palmitate Extended-Release Injectable Suspension 156 mg of Mylan Laboratories Limited, India and INVEGA SUSTENNA® (Paliperidone Palmitate)Extended-Release Injectable Suspension 156 mg of Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 in Subjects with Schizophrenia under Fasting Condition. - NA | CTRI/2018/05/013703 |
| Clinical study to evaluate the efficacy of dexamethasone Palmitate for idiopathic (immune) thrombocytopenic purpura: ITP. | Clinical Investigation to evaluate the efficacy of dexamethasone palmitate for idiopathic (immune) thrombocytopenic purpura: ITP. - Clinical investigation of Dexamethasone Palmitate for ITP | JPRN-jRCTs041190069 |
| The effects of palmitate and chicoric acid on diabetes | Investigation the effects of palmitate and cichoric acid on inflammation pathway in PBMCs of type2 diabetic patient and control group | IRCT2017071535085N1 |
| A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly | Cross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly | NCT03809325 |
| Bioequivalence study of Paliperidone Palmitate in schizophrenia patients | A multicenter, randomized, open label, two treatment, two period, two sequence, multiple-dose, two-way, crossover, steady-state bioequivalence study of Paliperidone Palmitate 156 mg/ml Injectable Suspension of Amneal Pharmaceuticals Company GmbH, with INVEGA® SUSTENNA® (paliperidone palmitate) extended-release injectable suspension 156 mg/ml Manufactured for Janssen Pharmaceuticals, Inc. Titusville, NJ 08560, USA in schizophrenia patients - 15-VIN-526 | CTRI/2019/02/017754 |
| Efficacy and safety of intra-articular injection of dexamethasone palmitate in promoting ERAS after knee arthroscopy | Efficacy and safety of intra-articular injection of dexamethasone palmitate in promoting ERAS after knee arthroscopy | ChiCTR2200056488 |
| A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs). | Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | EUCTR2018-004532-30-PL |
| A Study of Paliperidone Palmitate 6-Month Formulation | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | CTRI/2018/07/015058 |
| A randomized, open, controlled, multicenter clinical trial of intratympanic injection of dexamethasone palmitate in the treatment of sudden deafness | A randomized, open, controlled, multicenter clinical trial of intratympanic injection of dexamethasone palmitate in the treatment of sudden deafness | ChiCTR2200056554 |
| Generic drug trial to seek approval for Paliperidone 1 month injection for treatment of Schizophrenia. | A Pivotal, Single-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference Medicinal Product of Paliperidone Palmitate Prolonged-Release Injectable Suspension (100 mg) in Patients with Schizophrenia. | CTRI/2019/06/019840 |
| Generic drug trial to seek approval for Paliperidone injectable suspension for treatment of Schizophrenia or Schizoaffective Disorder. | A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference Listed Drug of Paliperidone Palmitate Extended-Release Injectable Suspension (156 mg) in Subjects with Schizophrenia or Schizoaffective Disorder | CTRI/2019/08/020588 |
| Pharmacokinetic study of Paliperidone Extended Release Injectable Suspension 156 mg in patients with schizophrenia and/ or schizoaffective disorder. | A multicenter, open label, randomized, balanced, two-treatment, two-period, two-sequence, multiple dose, steady state crossover bioequivalence study of Paliperidone Palmitate Extended Release Injectable Suspension 156 mg of Sun Pharmaceutical Industries Limited, India. with that of Invega Sustenna�® (Paliperidone Palmitate) Extended Release Injectable Suspension 156 mg of Janssen Pharmaceuticals, Inc. in patients with schizophrenia and/ or schizoaffective disorder - NIL | CTRI/2021/06/033960 |
| Can the drug Retinol Palmitate improve dryness and keratinization of the eye in patients with Chronic Stevens Johnson Syndrome | Evaluation of Retinol Palmitate Ophthalmic Suspension in Severe Dry Eye and Ocular Surface Keratinisation associated with Chronic Stevens Johnson Syndrome | CTRI/2021/11/038155 |
| A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings | Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings | NCT04940039 |
| A Bioequivalence in Patients with Schizophrenia already receiving a stable Regimen of Paliperidone Palmitate Extended Release Injectable Suspension. | A Randomized, Open Label, Two Stage, Multicentre, Parallel Group, Multiple Dose, Steady State Study to Compare Bioavailability and Characterize Pharmacokinetic Profile of Test Formulation[Paliperidone Palmitate Extended Release Injectable Suspension By Accord Healthcare,Administered Every Three Months] Relative to Reference Formulation [Invega Trinza®(Paliperidone Palmitate Extended Release Injectable Suspension) By Janssen Pharmaceuticals]and to Establish Bioequivalence in Patients with Schizophrenia Already Receiving A Stable Regimen of Paliperidone Palmitate Extended Release Injectable Suspension. | CTRI/2021/06/034105 |
| Effectiveness of long-acting paliperidone palmitate (PP1M) compared with oral antipsychotics on satisfaction, subjective well-being and service engagement in subjects with non-acute but symptomatic schizophrenia. | Efficacy on satisfaction, subjective well-being, and service engagement of long-acting paliperidone palmitate compared with oral antipsychotics: a randomized control study in schizophrenia | ACTRN12618001113246 |
| Generic drug trial seeking for approval of generic paliperidone 1 month injection for treatment of Schizophrenia. | A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference Medicinal Product of Paliperidone Palmitate Prolonged-Release Injectable Suspension (100 mg) in Subjects with Schizophrenia | CTRI/2019/06/019832 |
| Dexamethasone Palmitate for PONV After Craniotomy | Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy | NCT06988124 |
| Two-treatment Bioequivalence Study of Paliperidone Palmitate in adult schizophrenic patients | A Randomized, Open Label, Multicenter, Two-treatment, Single-period, Multiple Dose, Parallel, Steady State Bioequivalence Study of Paliperidone Palmitate (3-month) Extended Release Injectable Suspension for intramuscular use 546 mg (350 mg Paliperidone) (Pharmathen S.A., Greece) compared to TREVICTA�® 350 mg Prolonged Release Suspension for injection (Janssen-Cilag International NV, Belgium) in adult schizophrenic patients. | CTRI/2022/02/040103 |
| Preemptive Co-infiltration of Dexamethasone Palmitate With Ropivacaine for Postoperative Pain in Major Spinal Surgery | Preemptive Co-infiltration of Dexamethasone Palmitate Emulsion With Ropivacaine for Postoperative Pain in Patients Undergoing Major Spinal Surgery | NCT05693467 |
| Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery | Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery | NCT06981754 |
| Dexamethasone Palmitate for PONV After Open Surgery | Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Open Surgery | NCT06997419 |
| A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal | A Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal | NCT03666715 |
| Two-treatment Bioequivalence Study of Paliperidone Palmitate in adult schizophrenic patients | A Randomized, Open Label, Multicenter, Multiple Dose, Two Treatment, Two Period, Two Way, Crossover, Steady State Bioequivalence Study Between Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL of Eugia Pharma Specialities Limited, India and INVEGA SUSTENNA Paliperidone Palmitate Extended Release Intramuscular Injectable Suspension 156 mg per mL Manufactured for Janssen Pharmaceuticals, Inc Titusville, NJ 08560, USA in Adult Patients with Schizophrenia or Schizoaffective Disorder. - NIL | CTRI/2024/02/062550 |
| A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation | NCT03345979 |
| A double-blind randomized placebo controlled trial to investigate the effectiveness and safety of Retinyl Palmitate in patients with chronic Achilles tendinopathy | A double-blind randomized controlled trial to investigate the effectiveness and safety of Retinyl Palmitate in patients with chronic Achilles tendinopathy. | SLCTR/2023/016 |
| Fructose-Induced Palmitate Synthesis in Overweight Subjects | Fructose-Induced Palmitate Synthesis in Overweight Subjects | NCT00535535 |
| Adjunctive Dexamethasone Palmitate Use for Intercostal Nerve Block after Video-Assisted Thoracoscopic Surgery | Adjunctive Dexamethasone Palmitate Use for Intercostal Nerve Block after Video-Assisted Thoracoscopic Surgery | ChiCTR2300073478 |
| A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities | A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda | NCT03713658 |
| A study of Paliperidone Palmitate injection in patients of abnormal behavior | A randomized, open label, multicenter, parallel group, multiple dose, steady state study to compare the bioavailability and characterize the pharmacokinetic profile of the sponsorâ??s test formulation [Paliperidone Palmitate extended release injectable suspension, (156 mg/ml)] relative to that of the reference formulation [Invega® Sustenna® (Paliperidone Palmitate extended release injectable suspension, 156 mg/ml), Janssen Pharmaceuticals, Inc., Titusville, New Jersey] and establish bioequivalence in patients of Schizophrenia already receiving a stable regimen of paliperidone palmitate extended release injectable suspension. | CTRI/2019/01/016865 |
| Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris | Formulation of Retinyl Palmitate-loaded Topical Ethosomes for Treatment of Acne Vulgaris: a Split-face Comparative Clinical Study | NCT04080869 |
| Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection | Mirror-image Study Exploring Relapse and Resource Utilization of Paliperidone Palmitate and Risperidone Long-acting Injection in Vitalité Health Network Patients | NCT03390712 |
| Pharmacokinetic study of paliperidone palmitate in patients with schizophrenia. | A Randomized, Multicenter, Multiple-dose, Two-treatment, Parallel, Steady State Bioequivalence Study of Paliperidone palmitate ER Injectable Suspension (546 mg; Mylan) and INVEGA TRINZA ER Injectable Suspension (546 mg; Janssen Pharmaceuticals, Inc) in subjects with Schizophrenia. - Nil | CTRI/2018/08/015469 |
| PANDORA: Paravertebral AdjuNctive DexamethasOne Palmitate Reducing Chronic Pain After Caridiac Surgery | Effect of Continuous Paravertebral Nerve Block Combined With Dexamethasone Palpitate vs Combined With Dexamethasone Sodium Phosphate on Chronic Postoperative Pain in Patients Undergoing Minimally Invasive Cardiac Surgery | NCT05920967 |
| Two-treatment Bioequivalence Study of Paliperidone Palmitate in adult schizophrenic patients | A Randomized, Open Label, Multicenter, Multiple Dose, Two-stage, Two-treatment, Two-period, Two-way, Crossover Steady State Bioequivalence Study between Paliperidone Palmitate extended-release intramuscular injectable suspension (156 mg/mL) of American Regent, Inc. Shirley, NY 11967, USA & INVEGA SUSTENNA® Kit (paliperidone palmitate) extended release intramuscular injectable suspension (156 mg/mL) manufactured for Janssen Pharmaceuticals, Inc. Titusville, NJ 08560, USA in adult patients with schizophrenia and schizoaffective disorder. - NILL | CTRI/2023/06/054479 |
| A multicenter and real-world study on the efficacy and safety of paliperidone palmitate injection for schizophrenia | A multicenter and real-world study on the efficacy and safety of paliperidone palmitate injection for schizophrenia | ChiCTR2400092341 |
| Study of Paliperidone Palmitate injection 156mg/mL with INVEGA SUSTENNA® Injectable Suspension 156mg/mL in subjects with schizophrenia. | A multicenter, open label, balanced, randomized, two-treatment, single-period, parallel, steady-state bioequivalence study of Paliperidone Palmitate injection 156mg/mL of Qilu Pharmaceuticals Co., Ltd. with INVEGA SUSTENNA® (Paliperidone Palmitate) ER Injectable Suspension 156mg/mL of Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 in subjects with schizophrenia. - NA | CTRI/2020/05/025244 |
| Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia | A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia | NCT00589914 |
| Study of Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Metabolic Markers | Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Postprandial Lipemia, Haemostatic and Inflammatory Markers, Gut Hormone Concentrations, Satiety, and Insulinemic Response in Human Volunteers | NCT01428960 |
| Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia | Brain Myelination Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia | NCT01458379 |
| A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia | Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study | NCT01947803 |
| A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia | A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia | NCT00210717 |
| A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia | NCT00210548 |
| A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with Schizophrenia | A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with Schizophrenia | EUCTR2006-003560-62-HU |
| A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia | Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Subjects With Schizophrenia | NCT01942382 |
| Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia | NCT00590577 |
| Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia | A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia | NCT01515423 |
| A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia | A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia | NCT00604279 |
| 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years | A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse | NCT00946985 |
| A Prospective, Randomized, Active-controlled, Rater-blinded Study of thePrevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone inAdults with Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse | A Prospective, Randomized, Active-controlled, Rater-blinded Study of thePrevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone inAdults with Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse | EUCTR2008-007800-27-CZ |
| Prevention of Relapse with oral antipsychotics versus injectable paliperidone palmitate (PROSIPAL) | A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual with Oral Antipsychotics Monotherapy in Adults With Schizophrenia. | EUCTR2008-002247-16-DE |
| A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual with Oral Antipsychotics Monotherapy in Adults With Schizophrenia. | A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual with Oral Antipsychotics Monotherapy in Adults With Schizophrenia. - geen verkorte titel | NL-OMON32671 |
| The InterSat Study | The InterSat Study: Interesterified Fats: Health Effects of Commercially Relevant Palmitic Versus Stearic Acid Rich Interesterified Fats | NCT04418102 |
| The Effect of Paliperidone Palmitate in Schizophrenia | The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study | NCT01860781 |
| A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia | Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics | NCT01051531 |
| A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia | A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia | NCT01606254 |
| Saturated Fat Versus Monounsaturated Fat and Insulin Action | Palmitate Metabolism and Insulin Resistance | NCT01612234 |
| A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia | A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia | NCT01529515 |
| A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate | An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence | NCT01682161 |
| A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | EUCTR2009-017271-17-BG |
| A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia | An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia | NCT01150448 |
| A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia | A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia | NCT00119756 |
| PALMFlexS: Paliperidone Palmitate Flexible Dosing in Schizophrenia | A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated with oral or long-acting injectable antipsychotics - PALMFlexS | EUCTR2009-018022-30-PT |
| 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated | A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated | NCT01157351 |
| A prospective, open label, Phase IV multicentre efficacy and safety investigation of Paliperidone Palmitate long-acting injection in elderly people with schizophrenia. | A prospective, open label, Phase IV multicentre efficacy and safety investigation of Paliperidone Palmitate long-acting injection in elderly people with schizophrenia. | ACTRN12612001001886 |
| Relapse prevention study of paliperidone palmitate 3 Month formulation compared to placebo | A Radomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia | KCT0000544 |
| Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia | A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia | EUCTR2012-002785-12-SE |
| A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia | An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia | NCT01527305 |
| A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate | Open-Label, Parallel, Randomized, Multiple-Dose Pharmacokinetic Study of Paliperidone After Intramuscular Injection of Paliperidone Palmitate in the Deltoid or Gluteal Muscle in Subjects With Schizophrenia | NCT01110317 |
| A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics | Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up | NCT01685931 |
| Efficacy and Safety of an Infant Formula With Milkfat and Prebiotics | Safety and Efficacy of an Infant Starter Formula With Prebiotics (GOS) and a Higher Content of Beta-palmitate on Stool Characteristics, Food Tolerance, Calcium Uptake, and Incidence of Infectious Disease in the First Year of Life | NCT01603719 |
| A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia - Safety and tolerability of paliperidone palmitate in schizophrenia - deltoid vs gluteal injection. | A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia - Safety and tolerability of paliperidone palmitate in schizophrenia - deltoid vs gluteal injection. | EUCTR2005-001845-40-DE |
| Study of Paliperidone Palmitate 6 Month formulation for the Treatment of Patients with subjects schizophrenia (a type of mental disorder or illness characterized by abnormal social behavior and failure to understand what is real). | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation. | EUCTR2017-001941-28-DE |
| Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides, Beta-palmitate and Acidified Milk | Double-blind Randomized Controlled Study for the Evaluation of Nutritional Outcomes of a Cow's Milk Based Infant Formula Containing Galacto-oligosaccharides, Beta-palmitate and Acidified Milk | NCT01197365 |
| Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism | Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism: A Double-blind, Placebo-controlled, Randomized, Parallel Groups, Multi-center Study. | NCT01211704 |
| A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia | A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia | NCT01258920 |
| Effects of C16:0 versus C18:0 on HDL metabolism and other cardiometabolic risk markers: A dietary intervention study in healthy normal-weight and overweight subjects | Effects of C16:0 versus C18:0 on HDL metabolism and other cardiometabolic risk markers: A dietary intervention study in healthy normal-weight and overweight subjects - PASTEL (PAlmitic acid STEaric acid and Lipoproteins) | NL-OMON46224 |
| A study to evaluate the efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | CTRI/2011/091/000008 |
| An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia | NCT01299389 |
| Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures | Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients: A Randomized Clinical Trial | NCT01359293 |
| Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL) | A Quality Use of Medicine Clinical Registry to Assess Clinical Outcomes in Patients With Schizophrenia Treated With Intramuscular Injections of Paliperidone Palmitate | NCT01362426 |
| The effects of triacylglycerol structure of palmitic acid rich fats on postprandial changes in lipid and glucose metabolism | The effects of triacylglycerol structure of palmitic acid rich fats on postprandial changes in lipid and glucose metabolism - Dietary fats and postprandial metabolism | NL-OMON33469 |
| Effects of dietary fat structure on short term changes in blood lipids and insulin sensitivity | The acute effects of triacylglycerol structure of palmitic acid rich fats on postprandial changes in lipid and glucose metabolism: a randomised cross-over trial | ISRCTN20774126 |
| Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital | A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital | NCT01193166 |
| A Study of Paliperidone Palmitate 6-Month Formulation | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | NCT03345342 |
| A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. | A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion. | NCT00111189 |
| A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia | A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia | NCT01559272 |
| A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation. | A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation. - REMISSIO | EUCTR2015-004835-10-GB |
| Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia | Clinical and Cognitive Effects of Paliperidone Palmitate vs. Oral Risperidone in First-Episode Schizophrenia | NCT01451736 |
| Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia | NCT00101634 |
| The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers | Sensitivity to Fructose-Induced Palmitate Synthesis in End-Stage Renal Disease | NCT00234156 |
| Parenteral Retinol Level and Tolerability Trial | A Phase 2a, Open-label, Single-Arm Study Investigating Tolerability of IV/IM Administration of RetinolX (retinol palmitate) in Preterm Infants, and Measuring Serum Levels of Retinol, Retinol Palmitate and Retinol Binding Protein (RBP4) (PARELETO - Trial) - ASP-RET-CT001 | CTIS2024-516994-59-00 |
| Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia | Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia | NCT00073320 |
| Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate | Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate - A Pilot Study | NCT01448720 |
| The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis | The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis | NCT03080740 |
| A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, 37.5, 50 mg) Administered Every 2 weeks in Subjects with Schizophrenia - Non Inferiority Trial | A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, 37.5, 50 mg) Administered Every 2 weeks in Subjects with Schizophrenia - Non Inferiority Trial | EUCTR2004-002694-22-HU |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia | EUCTR2006-006434-17-RO |
| Interesterified fats: Health effects of commercially relevant palmitic versus stearic acid rich interesterified fats | Interesterified fats: Health effects of commercially relevant palmitic versus stearic acid rich interesterified fats - InterSat (Interesterified saturated fatty acids) | NL-OMON48329 |
| Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) | A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment | NCT02600741 |
| A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform | A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics | NCT02431702 |
| Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial. | Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial. - Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial. | JPRN-UMIN000015513 |
